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Background: Hematopoiesis is a complex process involving different cell types and feedback mechanisms mediated by
cytokines. This complexity stimulated various models with different scopes and applications. A combination of
complementary models promises to provide their mutual confirmation and to explain a broader range of scenarios. Here
we propose a combination of an ordinary differential equation (ODE) model of human granulopoiesis and an agent-
based model (ABM) of hematopoietic stem cell (HSC) organization. The first describes the dynamics of bone marrow cell
stages and circulating cells under various perturbations such as G-CSF treatment or chemotherapy. In contrast to the
ODE model describing cell numbers, our ABM focuses on the organization of individual cells in the stem population.
Results: We combined the two models by replacing the HSC compartment of the ODE model by a difference equation
formulation of the ABM. In this hybrid model, regulatory mechanisms and parameters of the original models were kept
unchanged except for a few specific improvements: (i) Effect of chemotherapy was restricted to proliferating HSC and (ii)
HSC regulation in the ODE model was replaced by the intrinsic regulation of the ABM. Model simulations of bleeding,
chronic irradiation and stem cell transplantation revealed that the dynamics of hybrid and ODE model differ markedly in
scenarios with stem cell damage. Despite these differences in response to stem cell damage, both models explain
clinical data of leukocyte dynamics under four chemotherapy regimens.
Conclusions: ABM and ODE model proved to be compatible and were combined without altering the structure of both
models. The new hybrid model introduces model improvements by considering the proliferative state of stem cells and
enabling a cell cycle-dependent effect of chemotherapy. We demonstrated that it is able to explain and predict
granulopoietic dynamics for a large variety of scenarios such as irradiation, bone marrow transplantation, chemotherapy
and growth factor applications. Therefore, it promises to serve as a valuable tool for studies in a broader range of clinical
applications, in particular where stem cell activation and proliferation are involved.Background
Hematopoietic stem cells (HSC) have been in the focus of
research since the beginning of last century [1]. Easy ac-
cessibility and handling, in combination with elegant ex-
perimental techniques like clonal assays [2,3] made the
hematopoietic system the best studied mammalian stem
cell system. As a consequence, the first models were de-
signed in the 1960s [4,5]. The process of hematological
homeostasis is characterized by a relative stability of the
(small) stem cell pool and a massive amplification along* Correspondence: axel.krinner@tu-dresden.de
1Institute for Medical Informatics and Biometry, TU Dresden, Blasewitzer Str.
86, D-01307 Dresden, Germany
Full list of author information is available at the end of the article
© 2013 Krinner et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orthe differentiation process, leading to a daily production of
about 1011-1012 mature blood cells [6]. This observation
led to the so called pedigree concept, which postulates
that stem cells originate only from stem cells, i.e. either
maintain the stem cell state or lose it irreversibly [7].
This concept represents a core assumption of most math-
ematical models for hematopoiesis that have been for-
mulated complementary to experiments. Some do not
explicitly model stem cells but include them as a source of
cellular influx into the modeled differentiation stages of
hematopoiesis [8-10]. Models that explicitly model the
hematopoietic stem cell population mostly focus on the cell
number of one [11,12], or more populations (such as a rest-
ing and proliferating cells [13]. Considering cell numbersLtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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A few models do consider structured cell populations and
introduce an additional cellular feature [14]. However, all
these models share the concept of unidirectional cell flux
towards differentiated states.
Following this concept, we also developed ordinary
differential equations (ODE) based lineage models of hu-
man granulopoiesis, erythropoiesis and thrombopoiesis
[15,16-19]. All these models are supplied by the same stem
cell model. They describe the dynamic regulation of HSC,
proliferating and maturing progenitors, mature blood cells
and cytokines of the hematopoietic system and aim at pre-
dicting the complex dynamics of hematopoiesis during
combined chemotherapy and growth factor applications.
A number of feedback loops control differentiation and
amplification, e.g. via the probability of stem cell self-
renewal, amplification rates and maturation times of com-
mitted cells. Models of pharmacokinetics and -dynamics
of growth factor and chemotherapy applications were in-
troduced recently, allowing precise predictions of clinical
data in numerous scenarios [19].
The strictly hierarchical pedigree concept was challenged as
experimental evidence for stem cell flexibility was found at
the end of the last century. Cells from neural [20], skeletal
[21,22] and vascular tissue [23] were shown to be capable of
engraftment in irradiated hosts and to contribute subse-
quently to the production of mature blood cells. Most likely
this flexibility is induced and controlled by the stem cell envir-
onment [24,25]. Our formerly developed agent-based model
(ABM) of hematopoietic stem cell organization incorporates
such a context dependent stem cell regulation by considering
two stem cell growth environments (GE) [26]. In one of these
two GE, which can be interpreted as a stem cell niche [24],
the stem cells are quiescent and regenerate their ability to re-
main in the niche, while in the other GE they proliferate and
lose this niche affinity. The broad range of successful applica-
tions of this modeling concept includes modeling of clonal
competition [27,28], age-dependent repopulation potential
after irradiation [29] and treatment of chronic myeloid
leukemia with Imatinib and interferon-α [30-32].
Certainly, the aim of systems biology and modeling is gen-
eration of consistent explanations for as many scenarios as
possible. Therefore, the following natural question arises
from the diversity of individual models and the different sce-
narios they explain: Can we assume their compatibility and
even expect synergistic advantages from their combination?
Desirably, the combined models should cover (many) com-
plementary scenarios for maximal synergistic effects, but
apply for the same scenarios for compatibility. Due to this
premise, we pursue this question with an attempt of second-
level modeling: a combination of our ODE model of human
granulopoiesis that follows the hierarchical paradigm and our
agent-based stem cell model. Both models were developed
on the basis of different biological evidence, experiments anddata and are well established. Thus our effort was to combine
them without changing their assumptions, equations, param-
eters and application scenarios as far as possible.
If the models prove to be compatible, we can expect the
mentioned synergistic effect for a set of reasons. The ODE
model turned out to be highly sensitive to changes in its
stem cell compartment (SCC) [17]. Exchanging its homo-
geneous stem cell population for a structured stem cell
model enables modeling of phenomena caused by hetero-
geneity within the SCC, such as lineage priming of stem
cells, clonal competition like leukemia development and
treatment or cell-cycle specific susceptibility to chemother-
apy or radiation. Although ODE model simulations of
granulocyte dynamics under chemotherapy agree well with
clinical data, predicted reduction of stem cell numbers ap-
pears to be over-estimated [33]. On the other hand, the
ABM does neither consider effects of growth factors nor
their pharmacokinetics. As a result, the ABM is not able to
correctly account for short-term effects in the reconstitu-
tion of blood cell number after chemotherapy which is
often supported by growth-factor applications. Besides,
ABM simulations for realistic cell numbers from stem cells
to differentiated cells are computationally expensive.
Therefore, we here propose an integration of these
model concepts guided by the motivation that systems-
biologic modeling is an iterative process. We substitute
the ODE stem cell model by a difference equation-based
formulation of the ABM describing continuous cell num-
bers [34]. By this approach, we expect to construct a more
comprehensive model with a broader range of possible ap-
plications, e.g. in the context of planning of clinical trials.
The adaptations necessary to combine the models will be
discussed in detail. We compare the new hybrid model with
the former ODE model in a number of qualitative tests, e.g.
with respect to chronic irradiation or bleeding. Finally, we
used the hybrid model to simulate four different chemo-
therapy regimens comprising both, dose and time intensifi-
cations of therapy and growth-factor applications as well.
Methods
In the following, we briefly explain our ODE model for
human granulopoiesis, our ABM stem cell model and its
difference formulation. Building on this background we
then establish our hybrid model.
ODE model for human granulopoiesis
We here summarize the central features of the ODE model
of human granulopoiesis. The complete set of equations
and parameters is given in the Appendix (A1.1 and A1.2).
All model assumptions are comprehensively discussed in
Scholz et al. [17]. The model describes the dynamics
of concatenated cell compartments by a set of ODEs
(Figure 1). Cell compartments represent cell numbers of
morphologically distinguishable cell stages of granulopoiesis,
Figure 1 Schematic representation of the ODE model. Compartments representing cell types and growth factors are depicted as boxes
(s. Table 1). Compartment MGB is substructured into G4-6 to model maturation with Γ-distributed transit times. Cell fluxes between compartments
are shown as black arrows, the effect of chemotherapy as gray arrows with associated kill rate kX indicated by a label and feedbacks as colored
arrows: intrinsic stem cell feedback (red), feedback from bone-marrow cells to stem cells (green) and feedback between later stages of
granulopoiesis mediated by explicitly modeled growth-factors (blue). The colored arrows indicate the input for the feedback functions
(s. Appendix A2.1) that dynamically control compartment parameters mentioned by the labels.
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in the bone marrow and mature granulocytes in periph-
eral blood (see Table 1) [17]. The two growth factors
granulocyte-macrophage colony stimulating factor (GM-
CSF) and granulocyte colony stimulating factor (G-CSF)
are also explicitly modeled and regulate amplification and
transit times in bone marrow compartments.
In all individual cell compartments, except for stem cells, a
general balance equation reflects the dynamics of growth, dif-
ferentiation and cell death due to chemotherapy: change in
compartment size = influx × amplification - efflux - cell loss.
Influx is given by the efflux of the upstream compart-
ment, while amplification and efflux of compartment X
are computed from the amplification-related parametersTable 1 List of all compartments in the ODE model and their
Compartment Meaning
S hematopoietic stem cells
CG granulopoietic progenitor cells
PGB proliferating granulopoietic precursor cells
MGB maturing granulopoietic precursor cells
GRA granulocytes
G CG + PGB + MGB
G-CSF G-CSF (granulocyte colony-stimulating factor)
GM-CSF GM-CSF (granulocyte, macrophage colony-stimulating facto
CX Chemotherapyproliferative fraction aX and amplification AX and the
residence-related parameters transit times TX (or in com-
partment S probability of self-renewal p). The stem cell
compartment represents the root of the hematopoietic tree
without influx. In this case, the first term of the balance
equation is simply replaced by proliferation/amplification.
Amplification and differentiation is controlled by the four
feedback loops sketched in Figure 1. Amplification and self-
renewal in the stem cell compartment are regulated by stem
cell number CS (Figure 1, red) and the number of granulo-
poietic bone marrow cells CG (Figure 1, green). A decrease/
increase in both cell numbers CS and CG results in an in-
crease/decrease, respectively, in proliferation, while the ef-
fects of CS and CG on self-renewal are contrary: low stembiological equivalents
Biological equivalents
hematopoietic stem cells
CFU-GM (colony forming units of granulocytes and macrophages)
myeloblasts, promyelocytes, precursor myelocytes
metamyelocytes (G4), banded (G5) and segmented (G6) granulocytes
granulocytes in circulation
total granulopoietic cells in bone marrow
cytokine of granulopoiesis
r) cytokine of granulopoiesis
(damaging effect of) chemotherapy
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ity than low bone marrow cell number CG causing increased
differentiation. These two feedback functions are adopted
from Wichmann and Loeffler (s. Appendix A1.1) [15].
The remaining two feedback loops (blue) control matur-
ation and amplification in the whole bone marrow except
for the SCC. They are mediated by the growth factors G-
CSF and GM-CSF (s. Appendix A1.1) [35-37]. G-CSF acts
in different modes: It increases proliferation, maturation
and the release of bone marrow cells to the blood. GM-
CSF regulates amplification in CG. Endogenous produc-
tion of both growth factors depends on cell numbers in
the bone marrow and the blood. Subcutaneous and in-
travenous G-CSF applications were included by a simple
pharmacokinetic model. We model a delayed influx from
the subcutaneous compartment by a two-compartment
system. Degradation in the central compartment is as-
sumed to happen unspecifically and specifically with the
specific degradation being proportional to the number of
circulating granulocytes. We assumed that applied G-CSF
acts in the same way as endogenous G-CSF, i.e. novel
G-CSF pharmaceuticals such as pegylated G-CSF with dif-
ferent pharmacodynamics were not considered here.
According to mouse data, chemotherapy was modeled as
an acute transient depletion of bone marrow cell stages fol-
lowing a first order kinetics depending on the drugs applied
and the cell compartments affected. (s. Appendix A1.1) [33].
All cell compartments are normalized with respect to
the setting CS = 1 in steady-state. Hence, all subsequent
compartments are given in units of equilibrium stem cellFigure 2 Scheme of the agent-based stem cell model and its coupling
one GE, niche affinity a < amax and cell cycle position c. The two GEs repres
with time and is limited by amax. In GE Ω it decreases and cells proliferate.
switch to Α and leave the stem cell compartment. In the hybrid model the
CX was modeled as cell loss in GE Ω without affecting GE A.number. Furthermore, we usually present relative compart-
ment sizes Cxrel =Cx / Cxnor. The steady-state values Cxnor
for all compartments X are given in the Appendix (A1.3).
The agent-based stem cell model
In contrast to the representation of the stem cell popula-
tion in the ODE model, our agent-based stem cell model
represents each cell individually. A general scheme of the
model is given in Figure 2. Each cell is characterized by
the growth environment GE that accommodates the cell
and a niche affinity a∈[amin, amax ] [26]. In each simulation
step the cells can either remain in or switch between the
two GEs. GE Α and Ω represent functionally distinct sig-
naling contexts and may be interpreted as a niche and a
non-niche environment, respectively. In the niche envir-
onment Α, cells are quiescent and regenerate niche affinity
a, while in the non-niche GE Ω they proliferate and lose
niche affinity. If a cell acquires an affinity lower than amin,
it loses its ability to switch back to Α, to regenerate affinity
a and to self-renew. Then it leaves the stem cell compart-
ment and enters further differentiation and amplification
stages. When a cell switches GEs, its affinity a remains
constant. The evolution of each cell’s affinity a at time t is
given by:
atþ1 ¼





for transitions A→Ωð Þ and Ω→Að Þ
8<
:
ð1Þin the hybrid model. Each cell is characterized by its affiliation to
ent functionally different environments: in GE Α affinity a increases
When a drops below the threshold a = amin, the cells lose the ability to
y enter the progenitor compartment CG. The effect of chemotherapy
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tiation coefficients, respectively. The cells at amax in GE
Α conserve their state unless they switch GEs.
The transitions between the GEs happen randomly
with transition intensities (probability per time step) that
depend on cell numbers in the target GEs and the indi-
vidual cell’s affinity. These dependences introduce an
intrinsic regulation of stem cell proliferation and dif-
ferentiation. For a cell of affinity a and a HSC popu-
lation of NΑ cells in GE Α and NΩ cells in GE Ω,
they are given by:
α a;NAð Þ ¼ aamax f α NAð Þ and
ω a;NΩð Þ ¼ amina f ω NΩð Þ
ð2Þ
where α and ω are the intensities of transitions Ω→
Α and Α→Ω, respectively. The functions fα and fω
model a limited capacity of both GEs approaching
zero for increasing cell numbers in the target envir-
onment. Their definition is given in the Appendix
(A2.1).
Because at amax the cells are quiescent and the probability
of their transition to Ω, and with it activation, is minimal,
these cells can be interpreted as dormant stem cells [38].
Proliferating cells in Ω are additionally characterized by
their cell cycle position c. In each simulation step it is sim-
ply increased by the time step: ct+1 = ct +Δt. The estab-
lished parameter set for human HSC assumes 48 h for a
complete cell cycle, which is divided into two sub-phases:
an intermediate G1-phase of 32 h (0 h ≤ c < 32 h) and a mi-
totic phase of 16 h (32 h ≤ c ≤ 48 h), subsuming S/G2/M-
phases [32]. During mitotic phase, no transitions to GE Α
are allowed. At the end of cell cycle, a cell divides into two
daughter cells. They inherit the affinity of their mother cell
and start cell cycle in G1-Phase (c = 0 h). If a cell switches
to GE Α, it always becomes quiescent. If a cell switches to
GE Ω, it enters the mitotic phase at c = 32.
A summary of all parameters of the stem cell model is
given in the Appendix (A2.2).
Difference equation formulation
When considering realistic cell numbers, simulations of
individual cells are computationally expensive. To replace
the ODE SCC we thus decided to use a difference formu-
lation of the ABM introduced in the last section which
was established by Kim et al. [34]. This difference formula-
tion is based on exactly the same equations and parame-
ters as the ABM. It reduces computational effort by
defining a discrete set of affinities and describing numbers
of cells of those affinities instead of individual cells of arbi-
trary affinities [34]. Considering Eq. (1) this discrete set is
constructed as follows:1. If a cell in GE Ω starts with maximal affinity amax =
a0 = 1 and does not change GE, it will adopt the
affinities ak = d
−k ; k∈ℕ0 and eventually leave GE Ω at
amin. Hence, defining k
max
d ¼ max k d−k > amingℕ
  ,
its niche affinities in GE Ω are fully described by the
set k∈ 0; 1;…; k maxd
 
with the associated affinities
ak = d
−k . Analogously, all niche affinities in A can
be mapped onto 0; 1;…; k maxr
 
with k maxr ¼
max k rk > amingℕ
  and the affinities ak = r−k.
2. If a cell switches GEs, its affinity is conserved (Eq.1)
and to set up the difference equations formulation
two matching sequences of affinities are required in
the two GEs. This is not the case in general, if d ≠ r.
But if ln r / ln d is a rational number with ln r / ln
d = v/w, the set of all possible affinities is given by
e−kρ; k∈ℕþ0
 
with ρ = ln r / v = ln d / w. The
established parameters of the human system are
r = 1.1 and d = 1.05 with ln r / ln d ≈ 2. Setting
ρ = 0.0488 results in the slightly modified coefficients
r = e2ρ = 1.10252 and d = eρ = 1.05001. Together with
amin = 0.002 from the human parameter set, this
results in kmax = 127.
Hence, the difference formulation describes the num-
ber of cells Αk and Ωk in compartments that are associ-
ated with the affinities
ak ¼ e−kp with k∈ 0; 1;…; 127f g ð3Þ
While the quiescent cells in GE Α are fully character-
ized by their affinity a, in GE Ω the cellular state is given
by the combination of affinity a and cell cycle position c.
The number Ωk of cells of affinity ak in Ω is subdivided
into the number of cells Ωk,c of cell cycle position c.
With c running from 0h to 48 h and a simulation time
step of Δt = 1 h this leads to 49 steps, a cell cycle dur-
ation of τ = 49 h and a 128 × 49 matrix Ωk,c of cellular
states. Thus, the cell numbers NΑ and NΩ that deter-
mine the transition characteristics are given by:
NA tð Þ ¼
X127
k¼0Ak tð Þ ð4Þ




c¼0Ωk;c tð Þ; ð5Þ
where Ak is the number of cells of affinity ak in GE Α
and Ωk,c is the number of cells of affinity ak and cell
cycle position c in GE Ω. For each value of ak, the tran-
sition probabilities α and ω are given by Eq. (2). For
computation time, we approximated the binomially dis-
tributed number of cells that switch GEs with their ex-
pectation values ω(ak,NΩ(t)) · Ak(t) and α(ak,NΑ(t)) ·Ωk,c
(t) for c = 0…31. These settings finally result in the fol-
lowing set of difference equations:
Αk t þ 1ð Þ ¼
Α0 tð Þ 1−ω 1;NΩ tð Þð Þð Þ þ Α1 tð Þ 1−ω e−ρ;NΩ tð Þð Þð Þ þ Α2 tð Þ 1−ω e−2ρ;NΩ tð Þð Þð Þ; k ¼ 0
Αkþ2 tð Þ 1−ω e− kþ2ð Þρ;NΩ tð Þ
  þX31
c¼0
Ωk;c tð Þ α e−kρ;NΑ tð Þ
 
; k ¼ 1;…; 125
X31
c¼0
Ωk;c tð Þ α e−kρ;NΑ tð Þ
 




Ωk;c t þ 1ð Þ ¼
Α0 tð Þ ω 1;NΩ tð Þð Þ;
2Ωk−1;48 tð Þ;
Ωk−1;c−1 tð Þ 1−α e− k−1ð Þρ;NΑ tð Þ
  
;
Ωk−1;31 tð Þ 1−α e− k−1ð Þρ;NΑ tð Þ
  þ Αk tð Þ ω e−kρ;NΩ tð Þ ;
Ωk−1;c−1 tð Þ;
0;
k ¼ 0; c ¼ 32
k > 0; c ¼ 0
k > 0; c ¼ 1;…; 31
k > 0; c ¼ 32
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In the hybrid model, the difference formulation of the
ABM introduced in the last section replaces the ODE
SCC. Accordingly, stem cell number CS is now given by
NS =NΑ +NΩ (see Eqs. (4) and (5)). Naturally, the new
SCC must comply with the coupling of SCC and other
compartments in the ODE model regarding cell fluxes,
chemotherapy effects and feedbacks (Figure 1).
Cells passing the threshold amin lose the ability to re-
turn to GE Α and to self-renew which means that they
enter subsequent maturation stages. They constitute the
efflux of the stem cell compartment NoutS and the influx
into the committed progenitor compartment CG. The
equilibrium efflux of the ABM stem cell compartment
N^ outS relative to equilibrium stem cell number N^ S is N^
out
S =
N^ S ¼ 0:003 h‐1 and, thus, considerably smaller than in
the ODE model (C^outS ¼ anorS =τS ¼ 0:01875 h‐1). However,
the stem cell uncertainty principle [39] makes is hard to
identify stem cells and, thus, their total number pre-
cisely. On the other hand, the ODE model normalizes
all cell numbers with regard to stem cell number, while
the ABM uses the parameters ÑΑ and ÑΩ for scaling
stem cell number which have no influence on qualita-
tive model behavior. Thus, we consider the discrepancy
in output as a scaling problem and decided to match
equilibrium efflux of the ABM with the one in the ODE
model by using the scaling parameter kscaling. Therefore,
in the hybrid model the efflux from S and influx to CG
given by:
CoutS tð Þ ¼ kscaling
NoutS tð Þ
NS tð ÞΔtABM with









it is assumed to be constant.
In the ODE model, chemotherapy causes a general re-
duction of the homogeneous stem cell population. The
difference equations model distinguishes between prolif-
erative and non-proliferative cells. Hence, it is possible
to model the effect of chemotherapeutic drugs by cell-
cycle specific toxicities [33]. In analogy to the ODE
model, we model chemotherapy as a transient first order
loss, but limited to proliferating cells in GE Ω. This is




k;c tn þ Δtð Þ ¼ 1−kSΨCXð Þ Ωk;c tnð Þ; ð9Þ
where ΨCX is the characteristic chemotherapy function
of the regimen considered (s. Appendix A1.1). Subse-
quently, all other processes such as transition between
GEs, cell divisions, differentiation and regeneration are
computed from this intermediate state.
Finally, feedback loops 1 and 2 of the ODE model
(Figure 1, red and green) remain to be integrated into
the hybrid model. Loop 1 is replaced by the intrinsic
regulation of the new SCC. To implement the effect of
feedback loop 2 in the hybrid model, we considered two
alternative mechanisms using the number of granulo-
poietic cells in the bone marrow as regulator. In analogy
to an increased proliferative fraction, the first one is
based on an activation of quiescent stem cells by regula-
tion of the transition probability ω. The second increases
activity in the SCC by a general acceleration of all pro-
cesses. Both concepts were tested extensively with vari-
ous feedback functions. It turned out that this feedback
loop, which is of clear importance for the ODE model,
can be dropped in the hybrid model without loss of ac-
curacy for the scenarios considered (see Discussion).
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brid model we did not perform any parameter fittings,
i.e. all parameter values derived from the ODE and
ABM model were preserved. This also applies for pa-
rameters required only for certain model scenarios such
as pharmacokinetic and –dynamic parameters of G-CSF
applications or chemotherapy toxicities.
Implementation and simulations
The hybrid model was implemented in Simulink 7.4 and
Matlab 7.9.0.529 (R2009b). Using the Simulink interface of
user defined S-functions we implemented the difference
equation formulation of the stem cell model as a Matlab
S-function. Simulations of the hybrid model were carried
out on SUSE Linux Enterprise Server 11 (×86 64). All pa-
rameters for the ODE model, the difference formulation
of the ABM and toxicities of drugs are given in A1.2, A2.2
and A3, respectively.
Results
A number of qualitative and quantitative simulations were
performed to study the behavior of our hybrid model in
comparison to the former ODE model. If not stated other-
wise, we present normalized cell numbers Crel in all figures.
Qualitative model behavior
Depletion of the granulocyte compartment
First, we considered an initial depletion of granulocytes
setting CGRA ¼ 10−15CnorGRA and initializing all other com-
partments with their equilibrium number Cnor. We com-
pared the two models regarding dynamics of granulocyte
recovery. In both models, the depleted granulocyte com-
partment is quickly repopulated after about 8 h and
equilibrates after a short overcompensation. Equilibrium
is reached after about 1d. Since the loss in granulocyte
numbers is signaled only via G-CSF to PGB and MGB,Figure 3 Responses of ODE and hybrid model after depletion of com
compartments are repopulated within 3d. a) In the ODE model, the feedba
damped oscillations. b) The hybrid model does not activate the SCC and t
without oscillations.the feedback to the SCC is not involved. Consequently,
the results of hybrid and ODE model are virtually identi-
cal (not shown).
Depletion of the granulocyte and maturing granulopoietic
precursor compartment
Next we simulated repopulation after a depletion of the
two latest stages of granulopoiesis (Figure 3). After initially
setting the cell numbers in GRA and all MGB subcom-
partments to 10-15 of their equilibrium values and all
remaining compartments to Cnor, the resulting repopula-
tion dynamics are more complex compared to the previ-
ous scenario. In the ODE model, the loss in compartment
MGB is transmitted to the SCC (Figure 1, green feedback
loop) and results in both, an increased proliferative frac-
tion and a decreased self-renewal in S (s. Appendix A1.1).
This induces an increased efflux and a reduction of S. In
consequence, the ODE model quickly repopulates after
about 3d, but the feedbacks cause damped oscillations for
approximately 80 days. Without the stem cell activation
via feedback 2, the hybrid model shows a very similar first
response except for the stem cell compartment, but no
oscillations occur.
Simulations of bone marrow transplantation
Because the differences between the models lie in the
two SCC, we addressed them directly by simulations
mimicking bone marrow transplantation with G-CSF
support after myeloablative conditioning. For this pur-
pose we initialized all bone marrow compartments with
1% and GRA with 50% of their equilibrium values. In all
simulations G-CSF was applied until recovery of gran-
ulocyte number is achieved. In the ODE model, G-CSF
was applied for 8 days. Under these conditions, the SCC
regenerates 50% of its equilibrium value after 18 days
and 100% after 61 days (Figure 4a). Due to the feedbackpartments MGB and GRA. In both models the depleted
ck to the SCC causes a transient decrease in stem cell number and
he perturbation has vanished in all compartments after ~23 days
Figure 4 Simulations of bone marrow transplantation with G-CSF support after myeloablative conditioning. All bone marrow
compartments were initialized with 1%, only GRA with 50% of its equilibrium value. We present relative cell numbers throughout. a) In the ODE
model, S repopulates 50% after 18d and 100% after 60d. GRA repopulates 50% after 6d and 100% after 7d. b) Both GEs in the SCC of the hybrid
model are reduced. Repopulation is slow and not completed after 100d. c) Stem cell reduction is limited to the proliferative GE Ω. S repopulates
98% in 5 days, PGB and GRA 100% after 9.5d. The other compartments repopulate within the next 40 days.
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occur. Repopulation of progenitor compartment CG is
similar to S. The more mature compartments PGB and
MGB recover faster than stem cells S and progenitors
CG. Mature granulocytes GRA recover 25% of their
equilibrium value after 4.6 days, 50% after 6 days and re-
populate completely after 7 days. If G-CSF application is
extended to 20 days, recovery dynamics does not change
in GRA, but clearly in the SCC despite of no direct ef-
fects of G-CSF on S. Regeneration in the SCC is acceler-
ated considerably, repopulating 50% after 13.5 days and
100% after only 19 days (data not shown).
Analogously, we tested the performance of the hybrid
model in this scenario (Figure 4b). In both GEs Α and Ω
of the SCC the content was reduced to 1% of its equilib-
rium value. Here, recovery is very slow compared to the
ODE model and not completed after 100d. Initially, only
GRA and CG decrease clearly. Stem cell number S de-
creases only slightly, because the cells found at low affin-
ities a in GE Ω rarely switch to Α, but rather leave the
SCC. After these cells have left the SCC, the intrinsic
regulation of the SCC first repopulates S before it gener-
ates progenitor cells again. Initially maximal amplifica-
tion allows cell numbers in PGB, MGB and GRA to
grow. Then the efflux of progenitor cells from S drops
to only approximately 0.05% of its equilibrium value and
causes a decline of all subsequent cell numbers. The
nadir propagates through all compartments eventually
reaching GRA, which starts to regenerate at d45.
If only Ω is reduced in the SCC, 82% of the stem cells
remain in GE Α, repopulate GE Ω and restore the efflux
of progenitors (Figure 4c). Reduced transit times in later
departments and increased amplification lead to a re-
population of GRA after only 10 days.
Hence, fundamentally different behavior arose from
those three scenarios. While recovery is fast in the ODEmodel, in the hybrid model it is not achieved within a
reasonable time frame, if all stem cells are reduced. If
only GE Ω is affected, maximal reduction of GRA is
similar to the ODE model, but stem cell dynamics are
largely different.
Preliminary adaptations of the hybrid model to this sce-
nario were motivated by the effect of myeloablation on the
bone marrow environment (s. Discussion). We altered the
transition characteristics of the SCC that model limited
capacities of both GEs. Without changing their values at
the equilibrium cell numbers, the feedback was made
more sensitive by increasing the sensitivity of the sigmoidal
transition characteristics to cell number (s. Appendix
A2.2). This resulted in much faster repopulation dynamics
after reduction of both GEs (s. Appendix, Figure 9). Higher
values of the transition characteristics at small cell num-
bers resulted in stem cell repopulation after 31 days and
recovery of 25% of granulocytes after 36 days. In these sim-
ulations the fast repopulation dynamics of the stem cell
compartment results in oscillations, too. However, we have
not elaborated this approach for application to bone mar-
row transplants, because here we limit ourselves to the
combination of the two models as a proof of principle.
Chronic irradiation
After single initial reductions we were interested in the
behavior of the system when exposed to a continuous
damage as in the case of chronic irradiation. In mice ir-
radiated with a daily dose of up to 0.6 Gy/d this continu-
ous damage results in a strong, dose-dependent decline
of CFU-S numbers during the first days of irradiation.
Then CFU-S numbers were found to stabilize at a lower
level (see [15] and references therein). Cell numbers of
later cell stages also decrease in a dose-dependent way,
but until a dose of about 0.6 Gy/d their cell numbers are
less sensitive compared to CFU-S. Then they decline
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until a certain threshold of damage, the system can com-
pensate the decline of CFU-S. We expect a similar be-
havior for human hematopoiesis and checked whether
the hybrid model can reproduce this behavior, too.
Following Wichmann and Loeffler, chronic irradiation is
modeled as a constant first order kill with rates kS in S and
kCG = kPGB = 0.66 kS in CG and PGB [15]. In the hybrid
model, we consider applications of the kill rate kS to either
both GEs or only to the proliferative GE Ω. For each sce-
nario, we recorded the contents of cell compartments after
100d. In the ODE model, S and CG show the same dose
dependence (Figure 5a). At small doses, their cell numbers
are highly sensitive to small dose-increments. At higher
doses the SCC responds to the stem cell loss by higher
proliferation and self-renewal and stabilizes at low stem
cell numbers until the system dies for kill rates kS >
0.025 h-1. At stem cell kill rates lower than 0.005 h-1 the
rapid loss of S and CG is compensated by increased prolif-
erative fractions and amplifications resulting in only
slightly reduced cell counts of circulating granulocytes
(GRA). For doses of 0.005 h-1 < kS < 0.025 h
-1 the loss can
no longer compensated and GRA starts to decline rapidly.
In contrast, in the hybrid model reduction in S is
smaller than in all other compartments and the greatest
cell loss is always found in CG (Figure 5b,c). During the
differentiation process the amplifying compartments
compensate this loss to some extent, too. If both GEs
are damaged, the system is more sensitive to the chronic
damage and collapses at kill rates an order of magnitude
smaller than the ODE model (Figure 5b). At a kill rate
kS ~ 10
-3 h-1 proliferation in GE Ω fails to counterbal-
ance the losses in both GEs, the SCC cannot stabilize
anymore and dies. If only GE Ω is affected, S itself is
very robust against irradiation, but the kill in GE Ω min-
imizes progenitor efflux. Yet at intermediate kill rates,Figure 5 Simulations of chronic irradiation. Constant kill rates are applie
PGB and GRA are recorded after 100 days. a) In the ODE model reductions
low doses. At higher doses cell numbers in PGB and GRA decrease rapidly.
compartments. b) If both GEs Α and Ω are damaged, the system is sensitiv
model. c) If damage is restricted to GE Ω, the SCC is more robust at kill rat
more sensitive in comparison to stem cells.this strong reduction of efflux cannot be compensated at
later cell stages (Figure 5c).
Quantitative modeling - application to chemotherapy data
After studying the behavior of the hybrid model qualita-
tively in comparison to the ODE model, we now apply it
quantitatively to clinical data provided by the NHL-B trial
of the German High Grade Non-Hodgkin-Lymphoma
Study Group [40,41]. Since one of us (M. Loeffler) is the
responsible biostatistician of this trial group, we have
access to raw patient data for our modeling purposes.
Leukocyte counts were determined in patients receiving
one of four CHOP-like multicycle polychemotherapy regi-
mens. The schedules differ in application of etoposide
(dose-intensification) and duration of therapy cycle (time-
intensification). The time-intensified regimens require
G-CSF support. For comparison with the normalized
simulation results leukocyte number is assumed to be pro-
portional to granulocyte number with normal value of
7000 leukocytes per μl blood [16]. Details of therapies can
be found in the Appendix, Table 5. The pooled patient
data is available online as supplemental data (s. Appendix:
Additional file 1).
Chemotherapy regimen without G-CSF
The hybrid model distinguishes between proliferative and
quiescent stem cells. For the mitosis-related effect of the
applied drugs we restrict their toxic effect on proliferating
stem cells. The effect of the three cytotoxic drugs applied
in the CHOP regimen is modeled by a single set of toxicity
parameters, one parameter for each compartment Ω, CG,
PGB and MGB. Toxicity parameters were taken from [17].
In particular, we used the same parameter value for toxicity
inΩ as for our former stem cell toxicity. The effect of pred-
nisone is modeled as a prolongation of granulocyte half-life
according to Bishop et al. [42] and Dale et al. [43]. Thed to S, CG and PGB (with kCG = kPGB = 0.66 kS). Cell numbers in S, CG,
in S and CG are similar. PGB and GRA almost maintain cell numbers at
b,c) In the hybrid model damage in S is smaller than in all other
e to kill rates that are an order of magnitude smaller than for the ODE
es comparable to those of the ODE model. All other compartments are
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clinical data are shown in Figure 6a. After an initial increase
of leukocytes due to prednisone application, the cell counts
decrease to about 10% of their normal value until day 11,
followed by a recovery phase until the start of the next
cycle. Model results fit well to the clinical data in the sense
that the model prediction is in the interquartile range of
the clinical data for almost all time points. For the CHOEP
regimen, an additional set of toxicity parameters represent-
ing the toxicity of the drug etoposide is used. Again, model
predictions fit well to clinical data applying the same tox-
icity parameters as used in Scholz et al. [17] (Figure 6b).
Chemotherapy regimen with G-CSF
The CHOP-14 and CHOEP-14 regimen use the same
schedule of drug administration, but reduce regeneration
time. The damage caused by this intensification is coun-
terbalanced by application of the growth factor G-CSF
between day 4 and day 13 of each cycle. Therefore we
have used the same toxicity parameters as for a cycle
duration of 21 days. G-CSF applications are covered by
the pharmacokinetic and -dynamic model of G-CSF pro-
vided by the ODE model and given in the Appendix
A1.1 [17]. Again, for both scenarios a good agreement of
hybrid model simulations and data was found for the
original toxicity parameters and without other adapta-
tions (Figure 7). Even though a completely different
model of stem cell organization and regulation was used
in the hybrid model, the resulting leukocyte dynamics
under chemotherapy is consistent with both, the ODE
model and the clinical data.
Comparison of stem cell dynamics during chemotherapy
To explain this phenomenon, we had a closer look at the
behavior of both SCCs and their effluxes in the course
of CHOP-21 simulations (Figure 8). During CHOP-21Figure 6 Comparison of the predictions of the hybrid model with clin
chemotherapy without G-CSF. Clinical data of a) CHOP-21 and b) CHOEP
percentiles) are compared with corresponding simulation results of the hyb
that they lie in the interquartile range of data for almost all time points. Ce
count value of healthy individuals (7000 cells/μl).application, total stem cell numbers in ODE and hybrid
model are reduced (Figure 8a). But while the ODE SCC is
almost eliminated, the SCC of the hybrid model maintains
the quiescent population and, thus, more than 80% of its
total number due to the limitation of cytotoxicity to prolif-
erating cells. Although proliferative cells are equally re-
duced in both models, in the hybrid model the quiescent
cells quickly repopulate the proliferative GE after the cyto-
toxic effect of drug administration has passed, and facili-
tate a nearly complete recovery in each cycle. In contrast,
the SCC of the ODE model has to regrow from only 0.23%
of its equilibrium population. Therefore it maximizes its
proliferative fraction aS and puts all cells to proliferation,
but even so it only restores about 20% of its equilibrium
population until the beginning of the next cycle.
Despite the huge differences in the dynamics of stem
cell numbers after chemotherapy, the effluxes of both
SCC show similar dynamics (Figure 8b). In the beginning
of each cycle both almost vanish and around day 7 both
increase rapidly to more than 50% of their equilibrium
value. At this time efflux is almost restored in the hybrid
model, because GE Ω recovered almost completely. In the
ODE model the feedback loops regulating proliferative
fraction aS and probability of self-renewal p allow an in-
crease of efflux to about 50% of its equilibrium value al-
though stem cell number CS is still around 10% of its
equilibrium value CrelS . In consequence, on the level of ma-
ture granulocytes, both models agree with each other and
the clinical data as well, because the differences in efflux
from the stem cell compartment are sufficiently small to
be compensated by the feedback controlled amplification
in subsequent bone marrow compartments.
Discussion
The number of attempts to model hematopoiesis
or hematopoietic sub-processes is considerable (e.g.ical data on leukocyte dynamics in peripheral blood during
-21 administration (Blue: median of patients, black: 25 and 75
rid model (red). Simulation results fit well to clinical data in the sense
ll numbers are normalized with respect to the average WBC/leukocyte
Figure 7 Comparison of the predictions of the hybrid model with clinical data on leukocyte dynamics in peripheral blood during
chemotherapy with G-CSF support. Clinical data of a) CHOP-14 and b) CHOEP-14 administration (Blue: median of patients, black: 25 and 75
percentiles) are compared with corresponding simulation results of the hybrid model (red). The effect of growth factor support is reflected by the
peak approximately one day after starting the G-CSF treatment at day 4 in each cycle. As for the regimens without G-CSF, simulation results fit
well to clinical data. Cell numbers are normalized with respect to the average WBC/leukocyte count value of healthy individuals (7000 cells/μl).
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tended to cover new scenarios [45,46,49-51]. However,
despite the often complementary scenarios covered by
yet existing models, little effort was made to unite them in
order to show their compatibility/consistency, to seek con-
firmation or to address open questions. Here, we pursue
such a cross-validation of two established models for
hematopoiesis developed in different contexts and on the
basis of different experimental data by combining them
into one comprehensive hybrid model for human granulo-
poiesis. The two models were chosen for their range of
clinically relevant applications, established parameter sets,
in particular for human hematopoiesis, and their comple-
mentary level of description. Rather than constructing a
model from scratch, we rely on these complementary
modeling works by adopting all their model assumptions,
equations and parameter settings. Therefore only adapta-
tions necessary to combine them were made. Due to the
different contexts in which the models were developed, itFigure 8 Comparison of stem cell dynamics in ODE and hybrid mode
and does not recover within one cycle. In the hybrid model, total stem cel
cells (blue) is similar to the ODE model, but regeneration is fast. b) Effluxes
after drug administration, but increase simultaneously around day 7.was by far not clear whether such an attempt will be suc-
cessful. Our approach can therefore be understood as a
second level of modeling by combining established models
in order to construct more comprehensive ones. To solve
this task, we examined different hypotheses for model
combination and performed a number of qualitative and
quantitative benchmark simulations to compare the hy-
brid model with the established ODE model, to test
whether the combined models are compatible and to
check whether the new hybrid model has potential to ex-
plain a broader range of scenarios.
The ordinary differential equation-based lineage model
for granulopoiesis developed by Scholz et al. [17] served
as the backbone of our hybrid model. This model de-
scribes the dynamics of cell stages from stem cells to cir-
culating granulocytes and the granulopoietic growth
factors G-CSF and GM-CSF. It succeeded in modeling
and prediction of a number of clinically relevant scenar-
ios of chemotherapy and G-CSF applications [17]. Thel. a) Stem cell number in the ODE model (green) is heavily reduced
l number (red) is only reduced to ~80%. Depletion of proliferative stem
from the ODE SCC (green) and the hybrid model (red) almost vanish
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tions of bone marrow compartments in dependence on
drugs and drug doses. Alternative approaches to model
chemotherapy are based on assumptions regarding in-
creased apoptosis and impaired proliferation. We relied
on our approach since our former modeling proved to
be successful in explaining clinical data sets of different
chemotherapies [16,17,19].
Because stem cells are represented as a homogenous
population, modeling of processes influenced by stem cell
heterogeneity such as cell cycle dependent drug toxicity is
difficult in the ODE framework. This was motivation
for us to combine it with a more detailed model of hema-
topoietic stem cells which was developed to understand
e.g. clonal competition and immune-chemotherapy effects
in leukemia treatment [27,28,32]. Combination is realized
by replacing the stem cell compartment of the ODE model
by a difference equation formulation of the agent-based
model of HSC organization [34].
Most of the hematopoietic models published so far do
not provide a detailed view on the stem cell level, since
they either do not model stem cell dynamics [8-10,14,48]
or treat them similarly simple as the ODE model [11,12].
We chose the ABM for HSC introduced by Roeder and
Loeffler [26] to replace the stem cell compartment of our
ODE for two reasons: it represents the stem cell popula-
tion in a highly structured way (two niches, affinity, cell
cycle) and has been proven successful in a broad range
of scenarios relevant for clinical applications such as
Imatinib-treatment of chronic myeloid leukemia in hu-
mans [30,32]. Replacement is performed on the basis of a
difference equations formulation of the ABM proposed by
Kim et al. [34]. Because the difference formulation con-
serves the ideas and behavior of the ABM, combination of
these different types of models (ABM, ODE) at different
scales (single cell, cell populations) is also interesting from
a general systems-biological point of view. The stem cell
models of Adimy [44] and Mackey [13] describe the stem
cell population with less detail, but are continuous alterna-
tives for substitution of the stem cell compartment of our
ODE model. We have also experimented with ODE
compartment models of proliferating and dormant stem
cells in the framework of a murine model of haemato-
poiesis under chemotherapy with fairly good results
(unpublished).
For similar computation times in both sub-models, we
chose to take advantage of two simplifications of the
ABM: (i) a difference formulation, which does not deteri-
orate accuracy [34] and (ii) the approximation of the prob-
abilistic transitions between GEs by their expectation
values. The first simplification impedes the analysis of in-
dividual cell fates and clonal contributions, but separate
matrices and parameter sets allow modeling of limited
numbers of stem cell subpopulations, such as leukemicand normal cells. The second makes the model determin-
istic and results in continuous cell numbers, but elimi-
nates stochastic variation among realizations that could be
interpreted as variation among individuals. However, if de-
sired, stochastic transitions can be easily re-established by
using binomially distributed random numbers.
A major challenge of our approach was to substitute
the feedback-loop signaling from more mature bone
marrow compartments back to stem cells. In the ODE
model this and the internal stem cell feedback control
proliferative fraction (aS) and self-renewal probability (p)
in the SCC (s. Appendix A1.1). Because the ABM pro-
vides an intrinsic regulation of proliferation and stem
cell maintenance, the stem cell feedback is replaced by
this internal regulation. To translate the feedback of the
bone marrow to stem cells into the hybrid model, we re-
interpreted the stem cell parameters aS and p of the
ODE model in terms of the new stem cell model. In the
ABM the proliferative fraction is given by the fraction
NΩ/( NΩ+ NΑ) of stem cells in GE Ω and is regulated by
the transitions between the GEs. These in turn are con-
trolled by the transition intensities α and ω. Accounting
for experimental results on activation of dormant HSC
after G-CSF stimulation [38], we first tested a depend-
ence of the probability ω for a transition Α→Ω on the
number of granulopoietic cells in the bone marrow.
However, simulations showed a long delay between stem
cell activation and increase of progenitor efflux. This
delay led to overcompensation at the level of granulo-
cytes and, thus, a clear deviation from the clinical data.
Alternatively we considered stem cell activation as an
acceleration of all processes in the ABM SCC. The
resulting shorter cell cycle and faster differentiation
leads to an increase in cell divisions in GE Ω and also
progenitor efflux from GE Ω. In combination with the
regulation of transition intensity ω, it reduces the over-
compensation mentioned above, but it does not eli-
minate it. Independent of this combination, it shifts the
granulocyte nadir after chemotherapy by an earlier in-
crease in production of progenitor cells. This causes
additional deviation from the clinical data. Both, regu-
lation of ω and acceleration, were implemented as
continuous piecewise functions of the bone marrow cel-
lularity G. In the sensitive range around equilibrium
conditions we tested linear and quadratic dependences
on bone marrow cellularity G. Outside this range we as-
sumed constant minimal and maximal values. Various
ranges and sensitivities of both feedback functions and
their combinations were tested, but it turned out that
the hybrid model agrees best with the quantitative data
after chemotherapy if the native stem cell regulation of
the ABM is used without an additional feedback. There-
fore, we decided to perform all simulations only with the
original stem cell regulation of the ABM.
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striction of the effect of chemotherapy to proliferating
cells, we did not introduce any modifications of both
sub-models, in particular with respect to parameter set-
tings. However, this substitution altered the number of
model parameters. With the ODE stem cell compart-
ment we eliminated eight parameters of the former ODE
model including those of loop 2, but introduced 16 pa-
rameters with the ABM model. Because these parame-
ters were neither fitted nor adapted, we added no
additional degrees of freedom to achieve a better fit to
the data. A fine tuning is possible, but contradicts the
idea of combining the models as a proof of compatibility
and confirmation. It might be necessary when applying
the hybrid model to new and more complex scenarios
not yet covered by both submodels, e.g. more complex
chemotherapies, diseased granulopoiesis and bone-
marrow transplantation (s. Section “Simulations of bone
marrow transplantation” and A4), which is planned for
the future.
In our qualitative simulations, we observed that after
damaging mature compartments, the recovery of circulat-
ing cells is similar under the former ODE model and the
new hybrid model. But at early cell stages, the ODE model
shows damped oscillations which do not occur for the hy-
brid model. Lack of data prevents us to decide which be-
havior is in better agreement with biological reality.
Main differences between the hybrid and the ODE
model arose after perturbations of the stem cell pool itself.
In our ODE model simulations of myeloablative bone
marrow transplants, the SCC repopulates completely
within approximately 50 days and GRA recovers its equi-
librium value after only 7 days. This is well below the
lower boundary of the wide range of recovery times for
absolute neutrophil count after bone marrow transplant-
ation [52,53]. While repopulation in the ODE model is too
fast, in the hybrid model it is far too slow. Only if damage
in the SCC is restricted to proliferating cells, reconstitu-
tion is completed within reasonable times. However, the
latter is not comparable to myeloablation since about 82%
of the stem cells remain unaffected. Myeloablation very
likely triggers a wide destruction of bone marrow struc-
ture and the niche environment as is known for irradiation
in mice [54-56]. Hence, our model does not cover this sce-
nario so far. It would require adaptations of the model
mechanisms that consider changes in environment and
signaling context. One approach could be a stronger de-
pendence of transitions on the capacity of the damaged
bone marrow niche after conditioning and, conse-
quently, a higher fraction of proliferative cells until the
niche is restored. In preliminary simulations we used
different transition characteristics with higher values for
low cell numbers without changes for equilibrium num-
bers (s. Appendix A4, Figure 9). Consequently, cells aremore likely to switch GEs, which can be interpreted as a
reduced ability of each GE to keep HSC in a stable state.
Driven by the instable quiescence the stem cells enabled
a recovery of 25% of granulocyte number within 36 days.
This is close to the upper boundary found in clinical
studies [52,53] and demonstrates the potential of the
hybrid model for applications to high-dose chemother-
apy and stem cell transplantation. The transition char-
acteristics of the new stem cell compartment control
the activation of stem cells and capacity of the two GEs.
They also determine the ratio of dormant and active
HSC and their rate of exchange. Hence, a detailed elab-
oration on changing growth environments and its appli-
cation to high-dose chemotherapy is possible, but goes
beyond the scope of this article.
Similar arguments hold for our qualitative simulations
of chronic irradiation. But here neither a relation of ex-
perimental irradiation dose and model toxicity parameters
nor a clear matching of model compartments and CFU-S
exists, so our results can only be interpreted in a qualita-
tive way. The compensation of stem cell loss by regulated
amplification in more committed compartments observed
for radiation experiments in mouse [15] is conserved in
the hybrid model if one identifies CFU-S with the com-
partment CG.
Despite the differences in stem cell dynamics for bone
marrow transplantation and chronic irradiation, quantita-
tive application of the hybrid model to clinical data of four
scenarios of conventional chemotherapies with and with-
out G-CSF treatment was successful. Here, we restricted
the damaging effect of chemotherapy to the proliferating
stem cell sub-compartment of the hybrid model and ap-
plied the stem cell kill rates estimated for the former ODE
model. This biologically more plausible approach of cell
cycle specific chemotherapeutic drugs in the hybrid model
avoids the apparently unrealistic reduction that is pre-
dicted by the ODE model [17,33]. We chose the CHOP-
like scenarios of the NHL-trial, because they can serve as
benchmark scenarios for the modeling of general, more
complex chemotherapies [17,19]. Agreement of hybrid
model and data was good for all chemotherapy regimens
without any adaptation of parameters and only the minute
change of model structure that were necessary for the
combination of the submodels.
The decision to drop the feedback of bone marrow
cellularity to stem cells was based on the comparison
with quantitative data of the CHOP-like chemotherapy
regimens. These regimens intend to maximally affect tu-
mors at the lowest toxicity for normal tissues. Hence, it
is conceivable that under these therapies, the bone mar-
row environment remains widely intact. Our results
therefore suggest that HSCs, in particular the dormant
subpopulation, represent an important population that is
highly protected and only activated after more severe
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mens. Activation of dormant HSCs only after heavy dam-
age also explains why diseases involving HSCs require
myeloablative therapies. For such strong damage, our pre-
liminary model simulations suggest a reduced stability and
activation of the dormant state due to this environmental
destruction, which is reflected in transition characteristics
that are more sensitive to bone marrow cellularity.
The reason for the agreement of the two models for the
four CHOP-like regimens is the similarity of efflux dynam-
ics of the two SCC. Both models agree on a proliferative
fraction of about 15% of the stem cells at equilibrium, too,
but assume different cycle times (8 h in the ODE model,
48 h in the ABM). Proliferative activity in the stem cell
compartment is computed from proliferative fraction and
cycle time. In both models, it covers a similar range, but
follows opposite dynamics during chemotherapy. The ODE
SCC activates all stem cells in order to regenerate the
nearly eliminated SCC and sends them into proliferation
(aS = 1), but is unable to recover within one chemotherapy
cycle. In contrast, the hybrid model predicts also a nearly
elimination of proliferating HSC (aS ~ 0) by the cytotoxic
drugs, but quickly repopulates them from quiescent cells
without activating more HSC than in equilibrium. Hence,
the two model scenarios suggest contrary hidden dynamics,
but both explain the clinical data equally well.
To evaluate which model better resembles biology in
the situation at hand, measurements of stem cell numbers
during chemotherapy would be required, which is impos-
sible for humans. Even if biopsies would be available for
analysis, the problem of identifying quiescent and prolifer-
ative HSC subpopulations and their cycle times remains.
Generally, the question of the ratio of quiescent and active
stem cells and their switching frequency is heavily dis-
cussed [38,57]. In the present situation, there are various
estimates, but mainly for mouse HSC which seem to differ
in many aspects from the human system [58,59]. Hence,
for the better availability of experimental data, an adapta-
tion of the model concept to the murine system is planned
for the future. The advantage of the hybrid model to dis-
tinguish between the two populations of quiescent and
proliferating stem cells becomes more powerful for mur-
ine hematopoiesis and related experimental possibilities.
Here it provides a well suited tool to study the equilibrium
of dormant/active HSC and its impact on hematopoiesis.
Insights from mouse modeling could later improve our
modeling in humans. This could result in a more universal
model of human granulopoiesis, whose clinical applica-
tions could go beyond existing models. Additionally, the
hybrid model will serve as the basis for a comprehensive
model of complete hematopoiesis by integrating the model
of stem cell lineage commitment and the other models of
hematopoietic lineages developed by our group since they
rely on the same stem cell model [15,17,18,47].Conclusions
In our hybrid model we have successfully combined two
complementary models for stem cell organization and
granulopoiesis by replacing the former stem cell compart-
ment of the lineage model and corresponding regulations.
The hybrid model features a novel combination of both, a
detailed representation of stem cells and the description of
later cell stages of granulopoiesis including the effect of
growth factor signaling. In particular, its representation
of stem cell states allows the modeling of cell cycle
dependent cytotoxic effects of chemotherapy. A number
of qualitative and quantitative simulations of the hybrid
model revealed very different behaviors of the former and
the new stem cell model. Nevertheless, quantitative appli-
cation of the hybrid model to four CHOP-like chemother-
apy regimens showed that the hybrid model explains the
clinically observed dynamics of leukocyte numbers equally
well. Model validation would require more detailed experi-
mental data on human HSC.
This novel combination paves the way for studying
not yet addressed scenarios such as high-dose chemo-
therapy, radiotherapy and diseased hematopoiesis. It
serves as another step towards a comprehensive model
of hematopoiesis comprising models of stem cell regula-
tion, lineage commitment, bone marrow cell popula-
tions, growth-factors and chemotherapy actions.
Appendix
A1. Details of the ODE model
A1.1 Model equations
The regulatory Z-function This regulatory function is
used to calculate amplification A in CG, PGB and sub-
compartment G6 in MGB as well as the transit time in












This representation allows regulating the quantity
Y ¼ Z Crelx
 
between a minimum and a maximum in





to Ynor. The parameter bY allows choosing different de-
grees of sensitivity. Details can be found in [17].
Characteristic function of chemotherapy Chemother-
apy is modeled in all compartments as a transient deple-
tion of cells following a first order kinetics. The rate of
this kinetics is given as the product of a kill rate kX (drug
and compartment specific) and a characteristic function
ΨCX modeling its time dependence:
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where ti are the time points of chemotherapy application.
If drugs are applied at different schedules, the different
chemotherapy functions are added.
Probability of self-renewal in S The probability of self-
renewal in the stem cell compartment S is controlled by
numbers of stem and granulopoietic cells in the bone
marrow:
p ¼ pδtanh −ϑS CrelS tð Þ−1
 
−ϑG CrelG tð Þ−1





for CrelS ≤ 1
for CrelS > 1
8<
:
The representation of p by tanh was used to regulate the
quantity symmetrically between a minimum and a max-
imum and to guarantee maximum sensitivity in steady-
state. See Wichmann/Loeffler for further details [34].
Proliferative fraction aX in compartments S and CG
Also the proliferative fraction aX in the compartments S
and CG is regulated by the numbers of stem and granu-
lopoietic cells in the bone marrow:











































−y þ aminX ey
e−y þ ey
This regulation was also adopted from Wichmann/
Loeffler p.65 [15] and Scholz et al. [17] respectively. In com-
partment X (=S or CG) the proliferative fraction aX is regu-
lated between a minimum and a maximum value, aminX and
amaxX . The quantity x represents the weighted logarithmic
relative size of the regulating compartments (S and G). The
normal value anorX and the value for intensified stimulation
a intX corresponding to x=−ln2 are fixed parameters, too.
Amplification splitting in all proliferating compart-
ments According to Scholz et al. amplification is always
divided into an amplification of the influx (“in”) and the
efflux (“out”) respectively (see [17] for further details).Stem cell compartment S
d
dt
CS ¼ 2p−1ð ÞCS aS
τS
−kSΨCXCS
CoutS ¼ 2 1−pð ÞCS
aS
τS
Granulopoietic progenitor cells CG











Proliferating granulopoietic precursor cells PGB











Maturing granulopoietic precursor cells MGB G4-6
To guarantee Γ-distributed transit times, the compart-
ments G4-6 are further subdivided into NG4, NG5 and
NG6 subcompartments (for details see [17]). While the
maturing time is regulated in all subcompartments,
amplification is regulated only in G6 (A < 1) which re-
flects post-mitotic apoptosis, while A = 1 in G4/G5.
Below the equation for G4 are given. The corresponding
equations for G5/G6 are obtained by replacing G4 with
G5/G6 and PBG with G4/G5, respectively.
TG4 ¼ ZTG4 CrelG−CSF
 


















for i ¼ 2;…;NG4
CoutG4 i ¼ AG4 iCG4 i
NG4
TG4
for i ¼ 1;…;NG4
CoutG4 ¼ CoutG4 NG4
Table 2 Parameter of the ODE model
Compartment Parameter value
S average duration of cell cycle τS 8 h
amplitude of regulation for
probability of self-renewal
Pδ 0.1
minimal proliferative fraction aminS 0.01
proliferative fraction at equilibrium anorS 0.15
proliferative fraction for intensified
stimulation
a intS 0.45
maximal proliferative fraction amaxS 1.0
weight of stem cells in p ϑS 2
weight of BM cells in p ϑG −10
weight of stem cells in a ωS 1
weight of bone marrow cells in a wG 0.4
CG minimal proliferative fraction aminS 0.3
proliferative fraction at equilibrium anorS 0.33
proliferative fraction for intensified
stimulation
aintS 0.6
maximal proliferative fraction amaxS 1
Minimal amplification Amin 1
equilibrium amplification Anor 64
maximal amplification Amax 333
sensitivity amplification bA 0.4
transit time T 112 h
PGB proliferative fraction a 1
minimal amplification Amin 4
equilibrium amplification Anor 32
maximal amplification Amax 330
sensitivity amplification bA 0.27
transit time T 148 h
MGB-G4 number of subcompartments NG4 5
amplification A 1
maximal transit time (at minimal
cell number)
Tmin 60 h
equilibrium transit time Tnor 51 h
minmal transit time Tmax 1 h
sensitivity transit time bT 0.845
MGB-G5 number of subcompartments NG5 5
amplification A 1
transit time Tmin 100 h
transit time Tnor 92 h
transit time Tmax 46 h
sensitivity transit time bT 0.845
MGB-G6 number of subcompartments NG6 5
minimal amplification Amin 0.01
equilibrium amplification Anor 0.4277
maximal amplification Amax 1
sensitivity amplification bA 1.52
Table 2 Parameter of the ODE model (Continued)
transit time Tmin 140 h
transit time Tnor 22 h
transit time Tmax 20 h
sensitivity transit time bT 0.845
GRA life-time Tnor 5 h
life time prolongation by Prednison TPred 0.66
GM-CSF maximal production rate Pmax 0.91 h-1
equilibrium production rate Pnor 1.0 h-1
minimal production rate Pmin 310 h-1
sensitivity production rate bP 1.7
life time TGM-CSF 2 h
weight of CG ωCG 1
weight of PGB ωPGB 1
weight of G4 ωG4 1
weight of G5 ωG5 1
weight of G6 ωG6 0.2
G-CSF maximal production rate Pmax 0.97 h-1
equilibrium production rate Pnor 1.0 h-1
minimal production rate Pmin 410 h-1




administered dose-equivalent dG-CSF 5.6 · 10
6
duration of G-CSF infusion tinf 2 min










weight of G6 ωG6 0.2
weight of GRA ωGRA 1







TGRA ¼ TnorGRA 1þ TPredGRA ΨPred
 
ΨPred is the characteristic function of prednisone
administration analogous to the characteristic func-
tion of chemotherapy (A2) but without first cycle ef-
fect (i.e. ffc = 1).
Table 4 Parameter of the stem cell compartment in the
hybrid model
Time step Δt 1 h
Differentiation coefficient d 1.10252
Regeneration coefficient r 1.05001
Threshold to differentiated cells amin 0.002
Maximum stem cell affinity amax 1.0
Cycle time τc 49 h
S/G2/M-phase τS 17 h
Transition Characteristics
Ω→ Α fΑ(0) 0.5
fΑ( ÑΑ /2) 0.45
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GM-CSF
PendoGM−CSF ¼ ZGM−CSF
 ωCGCCG þ ωPGBCPGB þ ωG4CG4 þ ωG5CG5 þ ωG6CG6
ωnorCGC
nor










Granulocyte Colony Stimulating Factor G-CSF The
model includes two G-CSF compartments: CG-CSF repre-
senting blood concentration and CSC for subcutaneous
G-CSF administration which is subdivided into CSC_1

















CSC 1 ¼ CexoSC −kSCCSC 1
d
dt
CSC 2 ¼ kSC CSC 1−CSC 2ð Þ




ti < t < ti þ t inf
otherwise

Where ti are the times when the infusions start and tinf
is the duration of G-CSF application. Degradation is
modeled by two independent processes, one dependent








TGRAG−CSFTable 3 Equilibrium values of all compartments
CGnor PRGnor MGBnor GRAnor Gnor GM-CSFnor G-CSFnor
50.4564 828.9625 4633.02 62.1161 5512.4 2.0 2.4383A1.2 Model parameter
In Table 2 we provide the full set of parameters
established by Scholz et.al. [17] and used in the simu-
lations of the ODE model. The identical set was used
without any adaptation in the simulations of the hy-
brid model.A1.3 Equilibrium values of all compartments
Evaluation of the parameters given in Table 2 leads to
the equilibrium numbers given in Table 3. Please note
that these numbers are given in units of equilibrium
stem cell number.A2. Details of the difference model
A2.1 Model equations
Transition functions
The general class of sigmoidal functions used for calcu-
lation of transition characteristics and transition inten-
sities is given by:
f Nð Þ ¼ 1
v1 þ v2 exp v3⋅ NeN
 þ v4Α→Ω fΩ(0) 0.5





Table 6 Toxicity parameter for simulations of the
CHOP-like regimens
Drug or drug combination kS kPGB kMGB
C750 + D50 + V2 0.1951 0.5 0.0
E100 0.005 1 0.005
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parameter νi, i = 1,…,4, which can be expressed more in-
tuitively by f (0), f (ÑΑ /2), f (ÑΑ) and f (∞) by
v1 ¼ h1h3−h22ð Þ= h1 þ h3−2h2ð Þ
v2 ¼ h1−v1;
v3 ¼ ln h3−v1ð Þ=v2ð Þ
v4 ¼ f ∞ð Þ;
with the auxiliary quantities
h1 ¼ 1= f 0ð Þ–f ∞ð Þ½ 
h2 ¼ 1= f ~N=2
 
–f ∞ð Þ 
h3 ¼ 1= f ~N
 
–f ∞ð Þ 
A2.2 Model parameter
The set of parameters used in the simulations of the hy-
brid model is given in Table 4. Please note again that
this is exactly the same parameter set as used in the
leukemia simulations of the ABM except for the small
changes in differentiation coefficient and regeneration
coefficient [32].
A3. Chemotherapy and toxicity parameter
A3.1 Schedule of the considered regimen
For quantitative simulations we have considered four estab-
lished chemotherapy regimen that serve as benchmarks,
because they comprise dose- and time-intensification of
therapy. Their schedules and cycle numbers as applied in
the NHL-B trial [40,41] are provided in Table in Table 5.
A3.2 Toxicity parameter
Scholz et.al. established the toxicity parameters given
in Table 6 for their simulations of the four CHOP-Table 5 Details of the four considered CHOP-like
chemotherapy regimens
Regimen G-CSF C D V E Pred cycles
CHOP-21 – 750 50 2 – 6
(398 patients) – d1 d1 d1 d 1-5 21d
CHOP-14 750 50 2 – 6
(393) d4-13 d1 d1 d1 d 1-5 14d
CHOEP-21 – 750 50 2 100 6
(387) – d1 d1 d1 d1-3 d 1-5 21d
CHOEP-14 750 50 2 100 6
(398) d4-13 d1 d1 d1 d1-3 d 1-5 14d
In the table the following abbreviations and related units are used: C:
Cyclophosphamide [mg/m2], D: Doxorubicin [mg/m2], V: Vincristine [mg], E:
Etoposide [mg/m2], Pred: Prednisone [mg]).like chemotherapy regimens which are summarized in
Table 5 [17]. We use exactly the same parameters in
our hybrid model simulations, including the first cycle
effect (ffc = 1.3).
A4. Preliminary simulation of high-dose chemotherapy
with bone marrow transplant
The damage induced by the CHOP-like chemotherapy
regimen appears to be small enough to render the
feedback from bone marrow cells to stem cells not
only unnecessary, but even distorting. For the stron-
ger damage conferred by myeloablative therapies the
response of the hybrid model can be accelerated by
an adaptation of the transition characteristics that
makes them more sensitive to changing cell numbers
(Figure 9). This adaptation does not influence equilib-
rium cell numbers, because values at equilibrium are
kept constant.Figure 9 Preliminary simulation of myeloablative bone marrow
transplant with modified transition characteristics. While
keeping the equilibrium values of the transition characteristics nearly
unchanged, for smaller cell numbers NΑ and NΩ the transition
characteristics increase much stronger than for the established
human parameter set. The more dynamic switching behavior results
effectively in stem cell activation and much faster recovery. Stem
cells repopulate completely after 31 days and GRA recovers 25% of
its equilibrium value after 36 days. Again G-CSF application was con-
tinued until the recovery of GRA.
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Additional file 1: Pooled patient data of the NHL-B trial of the
German High Grade Non-Hodgkin-Lymphoma Study Group for the
four considered chemotherapy regimen CHOP-21, CHOP-14,
CHOEP-21 and CHOEP-14. For each of the four regimens, median and
quartiles are supplied for each day for the duration of the protocol as
given in Appendix, Table 5.
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